查看购物车
  • Traditional Chinese
  • English
  • Japanese
多发性骨髓瘤市场:KOL的洞察
市场调查报告书
商品编码
1749303

多发性骨髓瘤市场:KOL的洞察

KOL Insight - Multiple Myeloma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

从抗CD38和CAR-T细胞疗法到双特异性抗体和抗体药物偶联物，本报告探讨了多发性骨髓瘤的关键进展如何塑造当前和未来的治疗途径。基于对来自美国和欧洲的12位关键意见领袖的采访，我们探讨了Darzalex的潜在扩张、BCMA靶向CAR-T细胞疗法日益增长的作用，以及吉利德/Arcellx、科济生物和阿斯特捷利康在研候选药物的前景。随着临床医师对疗效和安全性的不断改进，我们也关注了Tekbairi和Ellexfio等双特异性抗体以及葛兰素史克的Brenrep的再次崛起。深入了解未来3-5年骨髓瘤治疗的发展方向。

关键问题

  • 1.未来3-5年，骨髓瘤治疗领域最大的改变因素是什么？
  • 2.Darzalex 能否在高风险冒烟型骨髓瘤的治疗中扮演重要角色？
  • 3.Darzalex 在新诊断和復发患者中的定位如何演变？
  • 4.Sarclisa 能否与 Darzalex 竞争？
  • 5.KOL 如何看待伊比多胺和美齐多胺与先前的免疫疗法药物 (IMiD) 相比？
  • 6.CAR-T 细胞疗法在不久的将来将如何发展？
  • 7.靶向 BCMA 的双特异性抗体在早期治疗中的前景如何？
  • 8.鑑于对眼睛毒性的担忧，Brenerep 重返市场是否值得欢迎？

领导品牌

  • Darzalex（达雷妥尤单抗）
  • Sarclisa（伊沙妥昔单抗）
  • Calvicty（siltacabtagene autoleucel）
  • Avekuma（艾德卡布他单抗）
  • Tekbairi（泰克利司他单抗）
  • Ellexfio（厄拉那单抗）
  • Talbay（塔尔奎单抗）
  • Brenrep（贝兰他单抗）马福多汀)
  • 伊贝多胺
  • 美齐格多胺
  • 阿尼託卡比单抗 (CART-ddBCMA)
  • 泽伏他定单抗 (CT 053)
  • AZD0120
  • 阿洛卡比单抗 (Allocabtadine)
  • 利诺西汀 (Rinozyfic) (瑞博舍他单抗)
  • 依替米格
  • 西沃他单抗

调查手法

"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，就关键疾病领域的当前和未来治疗前景进行深入分析。 KOL 的筛选标准非常严格，包括全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与关键意见领袖 (KOL) 合作开发，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。每份报告发布后，我们都会持续进行12个月的市场监测，及时提供关键意见领袖 (KOL) 对重要新闻事件、市场变化和市场发展的更新。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够为您提供相关且有价值的洞察，帮助您掌握新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告为您提供所需的准确性和可靠性。独家存取独家访谈和数据，以及持续的市场监测，让您全面了解市场动态。我们的报告涵盖40多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。

简介目录

This report examines how key developments in multiple myeloma-ranging from anti-CD38 therapies and CAR T-cell treatments to bispecific antibodies and antibody-drug conjugates-are shaping current and future treatment pathways. Based on interviews with 12 KOLs in the US and Europe, it explores the potential expansion of Darzalex, the growing role of BCMA-targeting CAR T-cell therapies, and the outlook for pipeline candidates from Gilead/Arcellx, CARsgen, and AstraZeneca. It also considers the positioning of bispecific antibodies such as Tecvayli and Elrexfio, and the re-emergence of GSK's Blenrep, as clinicians weigh up evolving efficacy and safety profiles. Gain a clearer view of how the myeloma treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

  • 1. What are the biggest drivers of change in myeloma treatment over the next 3-5 years?
  • 2. Could Darzalex play a meaningful role in treating high-risk smouldering myeloma?
  • 3. How is Darzalex's position evolving across newly diagnosed and relapsed settings?
  • 4. Can Sarclisa compete with Darzalex, and will a subcutaneous option boost its uptake?
  • 5. How do KOLs view iberdomide and mezigdomide compared to older IMiDs?
  • 6. How will the use of CAR T-cell therapies shift in the near term?
  • 7. What is the outlook for BCMA-directed bispecific antibodies in earlier lines of therapy?
  • 8. Will Blenrep's re-entry into the market be welcomed despite ocular toxicity concerns?

Key Brands:

  • Darzalex (daratumumab)
  • Sarclisa (isatuximab)
  • Carvykti (ciltacabtagene autoleucel)
  • Abecma (idecabtagene vicleucel)
  • Tecvayli (teclistamab)
  • Elrexfio (elranatamab)
  • Talvey (talquetamab)
  • Blenrep (belantamab mafodotin)
  • iberdomide
  • mezigdomide
  • anitocabtagene autoleucel (CART-ddBCMA)
  • zevorcabtagene autoleucel (CT 053)
  • AZD0120
  • arlocabtagene autoleucel
  • Lynozyfic (linvoseltamab)
  • etentamig
  • cevostamab

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.